## Michael P Whyte

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6585447/publications.pdf

Version: 2024-02-01

209 papers

17,291 citations

20036 63 h-index 17373 126 g-index

216 all docs

216 docs citations

216 times ranked

11654 citing authors

#	Article	IF	CITATIONS
1	Hypophosphatasia: Vitamin B6 status of affected children and adults. Bone, 2022, 154, 116204.	1.4	9
2	Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 813-824.	1.8	36
3	Osteoprotegerin deficiency and aneurysm formation: Case report of iliac artery aneurysms in Juvenile Paget's disease. Annals of Vascular Surgery Brief Reports and Innovations, 2022, 2, 100065.	0.1	О
4	Periarticular calcifications containing giant pseudo-crystals of francolite in skeletal fluorosis from 1,1-difluoroethane †huffing†Bone, 2022, , 116421.	1.4	2
5	Skeletal and extraskeletal disorders of biomineralization. Nature Reviews Endocrinology, 2022, 18, 473-489.	4.3	25
6	Dysosteosclerosis: Clinical and Radiological Evolution Reflecting Genetic Heterogeneity. JBMR Plus, 2022, 6, .	1.3	2
7	Pharmacodynamics of asfotase alfa in adults with pediatric-onset hypophosphatasia. Bone, 2021, 142, 115664.	1.4	15
8	Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia. Calcified Tissue International, 2021, 108, 622-633.	1.5	26
9	Coalescing expansile skeletal disease: Delineation of an extraordinary osteopathy involving the IFITM5 mutation of osteogenesis imperfecta type V. Bone, 2021, 145, 115835.	1.4	7
10	Non-endemic skeletal fluorosis: Causes and associated secondary hyperparathyroidism (case report) Tj ETQq0 0	0 rgBT /Ον	verlock 10 Tf 5
11	Vitamin B6 deficiency with normal plasma levels of pyridoxal 5′-phosphate in perinatal hypophosphatasia. Bone, 2021, 150, 116007.	1.4	9
12	Adult hypophosphatasia treated with reduced frequency of teriparatide dosing. Journal of Musculoskeletal Neuronal Interactions, 2021, 21, 584-589.	0.1	1
13	Hypophosphatasia. , 2020, , 1569-1599.		3
14	Bruck syndrome 2 variant lacking congenital contractures and involving a novel compound heterozygous PLOD2 mutation. Bone, 2020, 130, 115047.	1.4	14
15	X‣inked Hypophosphatemia: Uniquely Mild Disease Associated With ⟨i⟩PHEX⟨/i⟩ 3′â€UTR Mutation c.*231A>G (A Retrospective Case–Control Study). Journal of Bone and Mineral Research, 2020, 35, 920-931.	3.1	12
16	Early-onset Paget's disease of bone in a Mexican family caused by a novel tandem duplication (77dup27) in TNFRSF11A that encodes RANK. Bone, 2020, 133, 115224.	1.4	7
17	Hypophosphatemic osteosclerosis, hyperostosis, and enthesopathy associated with novel homozygous mutations of DMP1 encoding dentin matrix protein 1 and SPP1 encoding osteopontin: The first digenic SIBLING protein osteopathy?. Bone, 2020, 132, 115190.	1.4	14
18	Growth Curves for Children with X-linked Hypophosphatemia. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 3243-3249.	1.8	26

#	Article	IF	CITATIONS
19	High bone mass from mutation of low-density lipoprotein receptor-related protein 6 (LRP6). Bone, 2020, 141, 115550.	1.4	22
20	Persistent idiopathic hyperphosphatasemia from bone alkaline phosphatase in a healthy boy. Bone, 2020, 138, 115459.	1.4	4
21	The two faces of giant cell tumor of bone. Cancer Letters, 2020, 489, 1-8.	3.2	20
22	Genetics of Skeletal Disorders. Handbook of Experimental Pharmacology, 2020, 262, 325-351.	0.9	3
23	<i>ZNF687</i> Mutations in an Extended Cohort of Neoplastic Transformations in Paget's Disease of Bone: Implications for Clinical Pathology. Journal of Bone and Mineral Research, 2020, 35, 1974-1980.	3.1	9
24	Hyperphosphatemia with low FGF7 and normal FGF23 and sFRP4 levels in the circulation characterizes pediatric hypophosphatasia. Bone, 2020, 134, 115300.	1.4	10
25	Healing of vitamin D deficiency rickets complicating hypophosphatasia suggests a role beyond circulating mineral sufficiency for vitamin D in musculoskeletal health. Bone, 2020, 136, 115322.	1.4	12
26	Juvenile Paget's Disease From Heterozygous Mutation of SP7 Encoding Osterix (Specificity Protein 7,) Tj ETQq0	0 0 rgBT /	Overlock 10 T
27	Tumor-Induced Osteomalacia: Treatment Progress Using Burosumab, an Anti-FGF23 Monoclonal Antibody. Journal of Bone and Mineral Research, 2020, 36, 625-626.	3.1	2
28	SAT-384 Identification of Heterozygous LRP5 Mutation and a TGF $\hat{I}^2$ -1 Variant of Unknown Significance in a Patient with Hearing Loss, High Bone Mass, and Oropharyngeal Exostoses. Journal of the Endocrine Society, 2020, 4, .	0.1	0
29	Skeletal fluorosis in a resettled refugee from Kakuma refugee camp. Lancet, The, 2019, 393, 223-225.	6.3	9
30	Absence of an osteopetrosis phenotype in IKBKG (NEMO) mutation-positive women: A case-control study. Bone, 2019, 121, 243-254.	1.4	4
31	New explanation for autosomal dominant high bone mass: Mutation of low-density lipoprotein receptor-related protein 6. Bone, 2019, 127, 228-243.	1.4	42
32	Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet, The, 2019, 393, 2416-2427.	6.3	229
33	No vascular calcification on cardiac computed tomography spanning asfotase alfa treatment for an elderly woman with hypophosphatasia. Bone, 2019, 122, 231-236.	1.4	11
34	Natural History of Perinatal and Infantile Hypophosphatasia: A Retrospective Study. Journal of Pediatrics, 2019, 209, 116-124.e4.	0.9	39
35	Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia. Bone, 2019, 121, 149-162.	1.4	99
36	Asfotase alfa for infants and young children with hypophosphatasia: 7 year outcomes of a single-arm, open-label, phase 2 extension trial. Lancet Diabetes and Endocrinology,the, 2019, 7, 93-105.	5.5	91

#	Article	IF	Citations
37	Efficacy and safety of burosumab in children aged 1–4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial. Lancet Diabetes and Endocrinology,the, 2019, 7, 189-199.	5 <b>.</b> 5	115
38	Genetic approaches to metabolic bone diseases. British Journal of Clinical Pharmacology, 2019, 85, 1147-1160.	1.1	21
39	MON-516 Skeletal Fluorosis from Fluorocarbon Inhalation. Journal of the Endocrine Society, 2019, 3, .	0.1	0
40	OR13-2 Burosumab Resulted in Greater Improvement in Rickets Than Conventional Therapy in Children with X-Linked Hypophosphatemia (XLH). Journal of the Endocrine Society, 2019, 3, .	0.1	0
41	Commentary. Clinical Chemistry, 2018, 64, 643-644.	1.5	1
42	Hypophosphatasia: Biochemical hallmarks validate the expanded pediatric clinical nosology. Bone, 2018, 110, 96-106.	1.4	36
43	Validation of a Novel Scoring System for Changes in Skeletal Manifestations of Hypophosphatasia in Newborns, Infants, and Children: The Radiographic Global Impression of Change Scale. Journal of Bone and Mineral Research, 2018, 33, 868-874.	3.1	33
44	Alkaline Phosphatase: Discovery and Naming of Our Favorite Enzyme. Journal of Bone and Mineral Research, 2018, 33, 362-364.	3.1	74
45	Gnathodiaphyseal dysplasia: Severe atypical presentation with novel heterozygous mutation of the anoctamin gene (ANO5). Bone, 2018, 107, 161-171.	1.4	23
46	Burosumab Therapy in Children with X-Linked Hypophosphatemia. New England Journal of Medicine, 2018, 378, 1987-1998.	13.9	339
47	Mendelian Disorders of RANKL/OPG/RANK/NF-κB Signaling. , 2018, , 453-468.		3
48	Hypophosphatasia and How Alkaline Phosphatase Promotes Mineralization., 2018,, 481-505.		15
49	Heritable Renal Phosphate Wasting Disorders. , 2018, , 761-782.		1
50	Unique Variant of <i>NOD2</i> Pediatric Granulomatous Arthritis With Severe 1,25-Dihydroxyvitamin D-Mediated Hypercalcemia and Generalized Osteosclerosis. Journal of Bone and Mineral Research, 2018, 33, 2071-2080.	3.1	9
51	Approach to the Patient With Metabolic Bone Disease. , 2018, , 887-902.		1
52	Sclerosteosis: Report of type 1 or 2 in three Indian Tamil families and literature review. Bone, 2018, 116, 321-332.	1.4	17
53	Hypophosphatasia: Enzyme Replacement Therapy Brings New Opportunities and New Challenges. Journal of Bone and Mineral Research, 2017, 32, 667-675.	3.1	110
54	Hypophosphatasia: An overview For 2017. Bone, 2017, 102, 15-25.	1.4	155

#	Article	IF	CITATIONS
55	Melorheostosis: Exome sequencing of an associated dermatosis implicates postzygotic mosaicism of mutated KRAS. Bone, 2017, 101, 145-155.	1.4	37
56	Skeletal Fluorosis Due To Inhalation Abuse of a Difluoroethane-Containing Computer Cleaner. Journal of Bone and Mineral Research, 2017, 32, 188-195.	3.1	25
57	Raine Syndrome (OMIM #259775), Caused By <i>FAM20C</i> Mutation, Is Congenital Sclerosing Osteomalacia With Cerebral Calcification (OMIM 259660). Journal of Bone and Mineral Research, 2017, 32, 757-769.	3.1	34
58	Osteopontin and the dento-osseous pathobiology of X-linked hypophosphatemia. Bone, 2017, 95, 151-161.	1.4	66
59	Idiopathic Acquired Osteosclerosis in a Middle-Aged Woman With Systemic Lupus Erythematosus. Journal of Bone and Mineral Research, 2016, 31, 1774-1782.	3.1	3
60	Auricular ossification: A newly recognized feature of osteoprotegerinâ€deficiency juvenile Paget disease. American Journal of Medical Genetics, Part A, 2016, 170, 978-985.	0.7	11
61	Adult Hypophosphatasia Treated with Teriparatide: Report of 2 Patients and Review of the Literature. Endocrine Practice, 2016, 22, 941-950.	1.1	47
62	Hypophosphatasia: Natural history study of 101 affected children investigated at one research center. Bone, 2016, 93, 125-138.	1.4	54
63	Commentary. Clinical Chemistry, 2016, 62, 688-688.	1.5	0
64	Asfotase Alfa Treatment Improves Survival for Perinatal and Infantile Hypophosphatasia. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 334-342.	1.8	189
65	Alkaline Phosphatase and Hypophosphatasia. Calcified Tissue International, 2016, 98, 398-416.	1.5	280
66	Neonatal High Bone Mass With First Mutation of the NF-κB Complex: Heterozygous De Novo Missense (p.Asp512Ser) <i>RELA</i> (Rela/p65). Journal of Bone and Mineral Research, 2016, 31, 163-172.	3.1	21
67	Hypophosphatasia — aetiology, nosology, pathogenesis, diagnosis and treatment. Nature Reviews Endocrinology, 2016, 12, 233-246.	4.3	346
68	Congenital insensitivity to pain: Fracturing without apparent skeletal pathobiology caused by an autosomal dominant, second mutation in SCN11A encoding voltage-gated sodium channel 1.9. Bone, 2016, 84, 289-298.	1.4	58
69	Hereditary Disorders of the Skeleton. , 2016, , 1173-1183.e4.		2
70	Asfotase alfa therapy for children with hypophosphatasia. JCI Insight, 2016, 1, e85971.	2.3	123
71	Response to: A Rapid Skeletal Turnover in Radiographic Mimic of Osteopetrosis Might Be Secondary to Systemic Mastocytosis. Journal of Bone and Mineral Research, 2015, 30, 946-946.	3.1	1
72	Lenz-Majewski Hyperostotic Dwarfism with Hyperphosphoserinuria from a Novel Mutation in <i>PTDSS1</i> Encoding Phosphatidylserine Synthase 1. Journal of Bone and Mineral Research, 2015, 30, 606-614.	3.1	17

#	Article	IF	CITATIONS
73	<i>&gt;PHEX</i> > 3′-UTR c.*231A&gt;G Near The Polyadenylation Signal Is a Relatively Common, Mild, American Mutation That Masquerades as Sporadic or X-Linked Recessive Hypophosphatemic Rickets. Journal of Bone and Mineral Research, 2015, 30, 137-143.	3.1	20
74	Factors influencing success of clinical genome sequencing across a broad spectrum of disorders. Nature Genetics, 2015, 47, 717-726.	9.4	310
75	Adaptor protein-2 sigma subunit mutations causing familial hypocalciuric hypercalcaemia type 3 (FHH3) demonstrate genotype–phenotype correlations, codon bias and dominant-negative effects. Human Molecular Genetics, 2015, 24, 5079-5092.	1.4	69
76	Hypophosphatasia: Validation and expansion of the clinical nosology for children from 25years experience with 173 pediatric patients. Bone, 2015, 75, 229-239.	1.4	199
77	Juvenile Paget's disease with heterozygous duplication within TNFRSF11A encoding RANK. Bone, 2014, 68, 153-161.	1.4	42
78	Calcific Periarthritis as the Only Clinical Manifestation of Hypophosphatasia in Middle-Aged Sisters. Journal of Bone and Mineral Research, 2014, 29, 929-934.	3.1	64
79	Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research. Journal of Bone and Mineral Research, 2014, 29, 1-23.	3.1	1,424
80	Multicentric carpotarsal osteolysis syndrome is caused by only a few domainâ€specific mutations in ⟨i⟩MAFB⟨ i⟩, a negative regulator of RANKLâ€induced osteoclastogenesis. American Journal of Medical Genetics, Part A, 2014, 164, 2287-2293.	0.7	36
81	Rapid Skeletal Turnover in a Radiographic Mimic of Osteopetrosis. Journal of Bone and Mineral Research, 2014, 29, 2601-2609.	3.1	12
82	Panostotic Expansile Bone Disease With Massive Jaw Tumor Formation and a Novel Mutation in the Signal Peptide of RANK. Journal of Bone and Mineral Research, 2014, 29, 911-921.	3.1	18
83	Severe skeletal toxicity from protracted etidronate therapy for generalized arterial calcification of infancy. Journal of Bone and Mineral Research, 2013, 28, 419-430.	3.1	74
84	Acute Severe Hypercalcemia After Traumatic Fractures and Immobilization in Hypophosphatasia Complicated by Chronic Renal Failure. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 4606-4612.	1.8	24
85	Outcome of Perinatal Hypophosphatasia in Manitoba Mennonites: A Retrospective Cohort Analysis. JIMD Reports, 2013, 11, 73-78.	0.7	52
86	Juvenile Paget's disease in an Iranian kindred with vitamin D deficiency and novel homozygous <i>TNFRSF11B</i> mutation. Journal of Bone and Mineral Research, 2013, 28, 1501-1508.	3.1	26
87	Hypophosphatasia., 2013,, 337-360.		26
88	Mendelian Disorders of RANKL/OPG/RANK Signaling. , 2013, , 309-324.		6
89	Pregnancy-Associated Osteoporosis With a Heterozygous Deactivating LDL Receptor-Related Protein 5 ( <i>LRP5</i> ) Mutation and a Homozygous Methylenetetrahydrofolate Reductase ( <i>MTHFR</i> ) Polymorphism. Journal of Bone and Mineral Research, 2013, 29, 922-928.	3.1	24
90	Enzyme-Replacement Therapy in Life-Threatening Hypophosphatasia. New England Journal of Medicine, 2012, 366, 904-913.	13.9	463

#	Article	IF	Citations
91	Dual-Energy X-Ray Absorptiometry Interpretation: A Simple Equation for Height Correction in Preteenage Children. Journal of Clinical Densitometry, 2012, 15, 267-274.	0.5	15
92	Whole-exome sequencing identifies mutations in the nucleoside transporter gene SLC29A3 in dysosteosclerosis, a form of osteopetrosis. Human Molecular Genetics, 2012, 21, 4904-4909.	1.4	81
93	Hypophosphatasia. , 2012, , 771-794.		22
94	Fibrodysplasia ossificans progressiva: Middle-age onset of heterotopic ossification from a unique missense mutation (c.974G &gt; C, p.G325A) in <i>ACVR1</i> . Journal of Bone and Mineral Researc 2012, 27, 729-737.	:h3.1	47
95	"Atypical femoral fractures―during bisphosphonate exposure in adult hypophosphatasia. Journal of Bone and Mineral Research, 2012, 27, 987-994.	3.1	159
96	Enzyme replacement prevents enamel defects in hypophosphatasia mice. Journal of Bone and Mineral Research, 2012, 27, 1722-1734.	3.1	74
97	Dose response of bone-targeted enzyme replacement for murine hypophosphatasia. Bone, 2011, 49, 250-256.	1.4	44
98	COL1 C-propeptide cleavage site mutations cause high bone mass osteogenesis imperfecta. Human Mutation, 2011, 32, 598-609.	1.1	119
99	Camurati-engelmann disease: Unique variant featuring a novel mutation in <i>TGFÎ<math>^2</math>1</i> encoding transforming growth factor beta 1 and a missense change in <i>TNFSF11</i> encoding RANK ligand. Journal of Bone and Mineral Research, 2011, 26, 920-933.	3.1	39
100	Hypophosphatasia: Nonlethal disease despite skeletal presentation in utero (17 new cases and) Tj ETQq0 0 0 rgB1	「/Overlocl 3.1	R 10 Tf 50 38
101	Skeletal Fluorosis from Brewed Tea. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 2318-2324.	1.8	44
102	Approach to the Patient with Metabolic Bone Disease., 2011,, 807-822.		1
103	Buschke-Ollendorff Syndrome. Archives of Dermatology, 2010, 146, 63-8.	1.7	30
104	Polycystic Bone Disease. Journal of Bone and Mineral Research, 2010, 15, 373-373.	3.1	1
105	Elevated serum lactate dehydrogenase isoenzymes and aspartate transaminase distinguish Albers-Sch¶nberg disease (Chloride Channel 7 Deficiency Osteopetrosis) among the sclerosing bone disorders. Journal of Bone and Mineral Research, 2010, 25, 2515-2526.	3.1	38
106	Dysosteosclerosis presents as an "Osteoclast-Poor―form of osteopetrosis: Comprehensive investigation of a 3-year-old girl and literature review. Journal of Bone and Mineral Research, 2010, 25, 2527-2539.	3.1	36
107	Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research. Journal of Bone and Mineral Research, 2010, 25, 2267-2294.	3.1	994
108	Physiological role of alkaline phosphatase explored in hypophosphatasia. Annals of the New York Academy of Sciences, 2010, 1192, 190-200.	1.8	294

#	Article	IF	CITATIONS
109	2009 Santa Fe Bone Symposium. Journal of Clinical Densitometry, 2010, 13, 1-9.	0.5	17
110	Hereditary Disorders of the Skeleton., 2010, , 1250-1260.		0
111	Atypical Femoral Fractures, Bisphosphonates, and Adult Hypophosphatasia. Journal of Bone and Mineral Research, 2009, 24, 1132-1134.	3.1	124
112	Chronic Recurrent Multifocal Osteomyelitis Mimicked in Childhood Hypophosphatasia. Journal of Bone and Mineral Research, 2009, 24, 1493-1505.	3.1	61
113	Enzyme Replacement Therapy for Murine Hypophosphatasia. Journal of Bone and Mineral Research, 2008, 23, 777-787.	3.1	222
114	Skeletal Fluorosis From Instant Tea. Journal of Bone and Mineral Research, 2008, 23, 759-769.	3.1	43
115	Bisphosphonate-Induced Osteopetrosis: Novel Bone Modeling Defects, Metaphyseal Osteopenia, and Osteosclerosis Fractures After Drug Exposure Ceases. Journal of Bone and Mineral Research, 2008, 23, 1698-1707.	3.1	88
116	Autosomal Recessive Hypophosphatasia Manifesting <i>in Utero </i> ii) with Long Bone Deformity but Showing Spontaneous Postnatal Improvement. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 3443-3448.	1.8	28
117	Hypophosphatasia. , 2008, , 1573-1598.		25
118	Infantile Hypophosphatasia: Transplantation Therapy Trial Using Bone Fragments and Cultured Osteoblasts. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2923-2930.	1.8	108
119	Sporadic Hyperphosphatasia Syndrome Featuring Periostitis and Accelerated Skeletal Turnover without Receptor Activator of Nuclear Factor-κB, Osteoprotegerin, or Sequestosome-1 Gene Defects. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1897-1901.	1.8	4
120	Adult Hypophosphatasia Treated with Teriparatide. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1203-1208.	1.8	149
121	Pyridoxine-responsive seizures as the first symptom of infantile hypophosphatasia caused by two novel missense mutations (c.677T>C, p.M226T; c.1112C>T, p.T371I) of the tissue-nonspecific alkaline phosphatase gene. Bone, 2007, 40, 1655-1661.	1.4	141
122	Juvenile Paget's Disease: The Second Reported, Oldest Patient Is Homozygous for the TNFRSF11B "Balkan―Mutation (966_969delTGACinsCTT), Which Elevates Circulating Immunoreactive Osteoprotegerin Levels. Journal of Bone and Mineral Research, 2007, 22, 938-946.	3.1	36
123	Recovery From Skeletal Fluorosis. Journal of Bone and Mineral Research, 2007, 22, 1476-1476.	3.1	1
124	Paget's Disease of Bone. New England Journal of Medicine, 2006, 355, 593-600.	13.9	126
125	Fluoride Levels in Bottled Teas. American Journal of Medicine, 2006, 119, 189-190.	0.6	7
126	Homozygosity for TNSALP mutation 1348c>T (Arg433Cys) causes infantile hypophosphatasia manifesting transient disease correction and variably lethal outcome in a kindred of black ancestry. Journal of Pediatrics, 2006, 148, 753-758.	0.9	36

#	Article	IF	CITATIONS
127	Low Serum Alkaline Phosphatase Activity and Pathologic Fracture: Case Report and Brief Review of Hypophosphatasia Diagnosed in Adulthood. Endocrine Practice, 2006, 12, 676-681.	1.1	56
128	Paget's Disease of Bone and Genetic Disorders of RANKL/OPG/RANK/NF-ÂB Signaling. Annals of the New York Academy of Sciences, 2006, 1068, 143-164.	1.8	84
129	Recovery From Skeletal Fluorosis (an Enigmatic, American Case). Journal of Bone and Mineral Research, 2006, 22, 163-170.	3.1	52
130	Deactivating Germline Mutations in LEMD3 Cause Osteopoikilosis and Buschke-Ollendorff Syndrome, but Not Sporadic Melorheostosis. Journal of Bone and Mineral Research, 2006, 22, 243-250.	3.1	74
131	Manifestations in a family with autosomal dominant bone fragility and limb-girdle myopathy. American Journal of Medical Genetics, Part A, 2006, 140A, 322-330.	0.7	9
132	Rare Bone Diseases., 2006,, 811-829.		0
133	Skeletal changes in epidermal nevus syndrome: Does focal bone disease harbor clues concerning pathogenesis?. American Journal of Medical Genetics, Part A, 2005, 139A, 67-77.	0.7	42
134	Misinterpretation of Osteodensitometry With High Bone Density. Journal of Clinical Densitometry, 2005, 8, 1-6.	0.5	43
135	Skeletal fluorosis and instant tea. American Journal of Medicine, 2005, 118, 78-82.	0.6	73
136	High Bone Mass. , 2005, , 147-150.		1
136	High-Bone Mass., 2005, , 147-150.  High-Bone-Mass Disease and LRP5. New England Journal of Medicine, 2004, 350, 2096-2099.	13.9	1 63
		13.9 9.4	
137	High-Bone-Mass Disease and LRP5. New England Journal of Medicine, 2004, 350, 2096-2099.  Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused		63
137	High-Bone-Mass Disease and LRP5. New England Journal of Medicine, 2004, 350, 2096-2099.  Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nature Genetics, 2004, 36, 377-381.  Oropharyngeal Skeletal Disease Accompanying High Bone Mass and Novel LRP5 Mutation. Journal of	9.4	1,257
137 138 139	High-Bone-Mass Disease andLRP5. New England Journal of Medicine, 2004, 350, 2096-2099.  Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nature Genetics, 2004, 36, 377-381.  Oropharyngeal Skeletal Disease Accompanying High Bone Mass and Novel LRP5 Mutation. Journal of Bone and Mineral Research, 2004, 20, 878-885.  Heritable disorders of the RANKL/OPG/RANK signaling pathway. Journal of Musculoskeletal Neuronal	9.4 3.1	63 1,257 57
137 138 139	High-Bone-Mass Disease andLRP5. New England Journal of Medicine, 2004, 350, 2096-2099.  Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nature Genetics, 2004, 36, 377-381.  Oropharyngeal Skeletal Disease Accompanying High Bone Mass and Novel LRP5 Mutation. Journal of Bone and Mineral Research, 2004, 20, 878-885.  Heritable disorders of the RANKL/OPG/RANK signaling pathway. Journal of Musculoskeletal Neuronal Interactions, 2004, 4, 254-67.  Marrow Cell Transplantation for Infantile Hypophosphatasia. Journal of Bone and Mineral Research,	9.4 3.1 0.1	63 1,257 57 37
137 138 139 140	High-Bone-Mass Disease andLRP5. New England Journal of Medicine, 2004, 350, 2096-2099.  Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nature Genetics, 2004, 36, 377-381.  Oropharyngeal Skeletal Disease Accompanying High Bone Mass and Novel LRP5 Mutation. Journal of Bone and Mineral Research, 2004, 20, 878-885.  Heritable disorders of the RANKL/OPG/RANK signaling pathway. Journal of Musculoskeletal Neuronal Interactions, 2004, 4, 254-67.  Marrow Cell Transplantation for Infantile Hypophosphatasia. Journal of Bone and Mineral Research, 2003, 18, 624-636.	9.4 3.1 0.1 3.1	<ul><li>63</li><li>1,257</li><li>57</li><li>37</li><li>155</li></ul>

#	Article	IF	CITATIONS
145	Familial Expansile Osteolysis (Excessive RANK Effect) in a 5-Generation American Kindred. Medicine (United States), 2002, 81, 101-121.	0.4	39
146	Denaturing Gradient Gel Electrophoresis Analysis of the Tissue Nonspecific Alkaline Phosphatase Isoenzyme Gene in Hypophosphatasia. Molecular Genetics and Metabolism, 2002, 75, 143-153.	0.5	66
147	Elevated plasma 4-pyridoxic acid in renal insufficiency. American Journal of Clinical Nutrition, 2002, 75, 57-64.	2.2	33
148	Expansile Skeletal Hyperphosphatasia Is Caused by a 15-Base Pair Tandem Duplication in TNFRSF11A Encoding RANK and Is Allelic to Familial Expansile Osteolysis. Journal of Bone and Mineral Research, 2002, 17, 26-29.	3.1	163
149	Clinical Delineation and Localization to Chromosome 9p13.3–p12 of a Unique Dominant Disorder in Four Families: Hereditary Inclusion Body Myopathy, Paget Disease of Bone, and Frontotemporal Dementia. Molecular Genetics and Metabolism, 2001, 74, 458-475.	0.5	191
150	Preonset Studies of Spondyloepiphyseal Dysplasia Tarda Caused by a Novel 2-Base Pair Deletion in SEDL Encoding Sedlin*. Journal of Bone and Mineral Research, 2001, 16, 2245-2250.	3.1	7
151	Pseudo-(Tumor-Induced) Rickets. Journal of Bone and Mineral Research, 2001, 16, 1564-1571.	3.1	11
152	Historical Vignette: Hypophosphatasia: Molecular Diagnosis of Rathbun's Original Case. Journal of Bone and Mineral Research, 2001, 16, 1724-1727.	3.1	33
153	Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nature Genetics, 2000, 24, 45-48.	9.4	457
154	Deficiency of the $\hat{l}_{\pm}$ -Subunit of the Stimulatory G Protein and Severe Extraskeletal Ossification. Journal of Bone and Mineral Research, 2000, 15, 2074-2083.	3.1	110
155	Expansile Skeletal Hyperphosphatasia: A New Familial Metabolic Bone Disease. Journal of Bone and Mineral Research, 2000, 15, 2330-2344.	3.1	63
156	"Cafî-Au-Lait Spots―Caused by Vitiligo in McCune-Albright Syndrome. Journal of Bone and Mineral Research, 2000, 15, 2521-2523.	3.1	0
157	Alkaline Phosphatase Knock-Out Mice Recapitulate the Metabolic and Skeletal Defects of Infantile Hypophosphatasia. Journal of Bone and Mineral Research, 1999, 14, 2015-2026.	3.1	343
158	Polycystic Bone Disease: A New, Autosomal Dominant Disorder. Journal of Bone and Mineral Research, 1999, 14, 1261-1271.	3.1	6
159	Mild autosomal dominant hypophosphatasia: In utero presentation in two families., 1999, 86, 410-415.		61
160	Mild hypophosphatasia mimicking severe osteogenesis imperfecta in utero: Bent but not broken. , 1999, 86, 434-438.		70
161	Bilateral radial ray hypoplasia with multiple epiphyseal dysplasia. , 1998, 77, 182-187.		6
162	Skeletal Disorders Characterized By Osteosclerosis Or Hyperostosis., 1998,, 697-739e.		11

#	Article	IF	CITATIONS
163	Calcinosis Universalis Complicating Juvenile Dermatomyositis: Resolution During Probenecid Therapy1. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 3536-3542.	1.8	52
164	Extraskeletal Osteoclastomas Responsive to Dexamethasone Treatment in Paget Bone Disease1. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 3826-3834.	1.8	17
165	Paget Bone Disease Involving Young Adults in 3 Generations of a Korean Family. Medicine (United) Tj ETQq1 1 0.	784314 rg	gBT/Overloc
166	Searching for Gene Defects That Cause High Bone Mass. American Journal of Human Genetics, 1997, 60, 1309-1311.	2.6	29
167	Linkage Studies of a Missouri Kindred with Autosomal Dominant Spondyloepimetaphyseal Dysplasia (SEMD) Indicate Genetic Heterogeneity. Journal of Bone and Mineral Research, 1997, 12, 1204-1209.	3.1	10
168	Surgical management of calcinosis cutis universalis in systemic lupus erythematosus. Arthritis and Rheumatism, 1997, 40, 570-572.	6.7	37
169	Juvenile paget disease: Life-long features of a mildly affected young woman. Journal of Bone and Mineral Research, 1996, 11, 132-142.	3.1	46
170	Doubling skeletal mass during adult life: The syndrome of diffuse osteosclerosis after intravenous drug abuse. Journal of Bone and Mineral Research, 1996, 11, 554-558.	3.1	37
171	Absence of paramyxo virus transcripts in juvenile paget bone disease. Journal of Bone and Mineral Research, 1996, 11, 1041-1041.	3.1	6
172	Creatine kinase brain isoenzyme (BB-CK) presence in serum distinguishes osteopetroses among the sclerosing bone disorders. Journal of Bone and Mineral Research, 1996, 11, 1438-1443.	3.1	54
173	Linkage studies in a kindred from Oklahoma, with familial benign (hypocalciuric) hypercalcaemia (FBH) and developmental elevations in serum parathyroid hormone levels, indicate a third locus for FBH. Human Genetics, 1995, 96, 183-187.	1.8	61
174	Infantile hypophosphatasia: Successful prenatal assessment by testing for tissue-non-specific alkaline phosphatase isoenzyme gene mutations. Prenatal Diagnosis, 1995, 15, 1001-1006.	1.1	50
175	Hypophosphatasia and the Role of Alkaline Phosphatase in Skeletal Mineralization*. Endocrine Reviews, 1994, 15, 439-461.	8.9	425
176	Mutation analysis of coding sequences for type I procollagen in individuals with low bone density. Journal of Bone and Mineral Research, 1994, 9, 923-932.	3.1	94
177	Evidence against a role for alkaline phosphatase in the dephosphorylation of plasma membrane proteins: Hypophosphatasia fibroblast study. Journal of Cellular Biochemistry, 1993, 53, 43-50.	1.2	18
178	Painful diffuse osteosclerosis after intravenous drug abuse. American Journal of Medicine, 1992, 93, 371-381.	0.6	45
179	X-linked hypophosphatemic rickets: A study (with literature review) of linear growth response to calcitriol and phosphate therapy. Journal of Bone and Mineral Research, 1992, 7, 583-597.	3.1	82
180	Hypercalciuria in children severely affected with osteogenesis imperfecta. Journal of Pediatrics, 1991, 119, 51-57.	0.9	49

#	Article	IF	CITATIONS
181	X-linked hypophosphatemia: skeletal mass in adults assessed by histomorphometry, computed tomography, and absorptiometry. American Journal of Medicine, 1991, 90, 63-69.	0.6	69
182	Hypophosphatasia and the Extracellular Metabolism of Inorganic Pyrophosphate: Clinical and Laboratory Aspects: Part I. Critical Reviews in Clinical Laboratory Sciences, 1991, 28, 175-194.	2.7	98
183	Normal left ventricular performance in children with x-linked hypophosphatemic rickets: A doppler echocardiography study. Journal of Bone and Mineral Research, 1990, 5, 469-474.	3.1	32
184	Infantile hypophosphatasia: Autosomal recessive transmission to two related sibships. American Journal of Medical Genetics Part A, 1990, 36, 15-22.	2.4	42
185	Hypotrichosis with spondyloepimetaphyseal dysplasia in three generations: A new autosomal dominant syndrome. American Journal of Medical Genetics Part A, 1990, 36, 288-291.	2.4	15
186	First Identification of a Gene Defect for Hypophosphatasia: Evidence That Alkaline Phosphatase Acts in Skeletal Mineralization. Connective Tissue Research, 1989, 21, 99-106.	1.1	25
187	X-Linked Hypophosphatemia. Medicine (United States), 1989, 68, 336-352.	0.4	125
188	Central osteosclerosis with ectodermal dysplasia: Clinical, laboratory, radiologic, and histopathologic characterization with review of the literature. Journal of Bone and Mineral Research, 1989, 4, 863-875.	3.1	17
189	Alkaline phosphatase is an ectoenzyme that acts on micromolar concentrations of natural substrates at physiologic pH in human osteosarcoma (SAOS-2) cells. Archives of Biochemistry and Biophysics, 1988, 264, 400-409.	1.4	95
190	Infantile hypophosphatasia: Enzymatic defect explored with alkaline phosphatase-deficient skin fibroblasts in culture. Calcified Tissue International, 1987, 40, 244-252.	1.5	26
191	Infantile hypophosphatasia fibroblasts proliferate normally in culture: Evidence against a role for alkaline phosphatase (tissue nonspecific isoenzyme) in the regulation of cell growth and differentiation. Calcified Tissue International, 1987, 40, 1-7.	1.5	26
192	Infantile hypophosphatasia: Normalization of circulating bone alkaline phosphatase activity followed by skeletal remineralization. Journal of Pediatrics, 1986, 108, 82-88.	0.9	57
193	Normal Activity of Nucleoside Triphosphate Pyrophosphatase in Alkaline Phosphatase-Deficient Fibroblasts from Patients with Infantile Hypophosphatasia*. Journal of Clinical Endocrinology and Metabolism, 1986, 63, 1237-1241.	1.8	23
194	Macroepiphyseal dysplasia with symptomatic osteoporosis, wrinkled skin, and aged appearance: A presumed autosomal recessive condition. Skeletal Radiology, 1986, 15, 47-51.	1.2	7
195	Carbonic Anhydrase II Deficiency in 12 Families with the Autosomal Recessive Syndrome of Osteopetrosis with Renal Tubular Acidosis and Cerebral Calcification. New England Journal of Medicine, 1985, 313, 139-145.	13.9	298
196	Enzyme replacement therapy for infantile hypophosphatasia attempted by intravenous infusions of alkaline phosphatase-rich Paget plasma: Results in three additional patients. Journal of Pediatrics, 1984, 105, 926-933.	0.9	90
197	Hypophosphatasia. Medicine (United States), 1984, 63, 12-24.	0.4	115
198	Alkaline Phosphatase Deficiency in Cultured Skin Fibroblasts from Patients with Hypophosphatasia: Comparison of the Infantile, Childhood, and Adult Forms*. Journal of Clinical Endocrinology and Metabolism, 1983, 57, 831-837.	1.8	33

#	Article	IF	CITATIONS
199	Circulating Vitamin D Metabolite Levels in Hypophosphatasia*. Journal of Clinical Endocrinology and Metabolism, 1982, 55, 178-180.	1.8	28
200	Infantile hypophosphatasia: Enzyme replacement therapy by intravenous infusion of alkaline phosphatase-rich plasma from patients with Paget bone disease. Journal of Pediatrics, 1982, 101, 379-386.	0.9	77
201	Adult hypophosphatasia with chondrocalcinosis and arthropathy. American Journal of Medicine, 1982, 72, 631-641.	0.6	97
202	Postmenopausal osteoporosis. American Journal of Medicine, 1982, 72, 193-202.	0.6	185
203	Mixed-sclerosing-bone-dystrophy: Report of a case and review of the literature. Skeletal Radiology, 1981, 6, 95-102.	1.2	48
204	Biochemical and Ultrastructural Demonstration of Elastin Accumulation in the Skin Lesions of the Buschke-Ollendorff Syndrome. Journal of Investigative Dermatology, 1981, 76, 284-287.	0.3	71
205	Osteopetrosis, renal tubular acidosis and basal ganglia calcification in three sisters. American Journal of Medicine, 1980, 69, 64-74.	0.6	109
206	Adult Hypophosphatasia. Medicine (United States), 1979, 58, 329-347.	0.4	118
207	Idiopathic Multicentric Osteolysis. Arthritis and Rheumatism, 1978, 21, 367-376.	6.7	27
208	Heritable Forms of Rickets and Osteomalacia. , 0, , 765-787.		6
209	Hypophosphatasia: a retrospective natural history study of the severe perinatal and infantile forms. Bone Abstracts, 0, , .	0.0	6